story of the week
Sapanisertib Plus Fulvestrant in Women With Advanced Breast Cancer After Progression on Aromatase Inhibitor
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
Clin. Cancer Res 2022 Jan 03;[EPub Ahead of Print], JÁ García-Sáenz, N Martínez-Jáñez, R Cubedo, Y Jerez, A Lahuerta, S González-Santiago, N Ferrer, M Ramos, JL Alonso-Romero, A Antón, E Carrasco, J Chen, R Neuwirth, K Galinsky, S Vincent, EJ Leonard, D SlamonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.